11:20 AM EDT, 07/25/2024 (MT Newswires) -- Pfizer's ( PFE ) said Thursday the European Commission has granted conditional marketing authorization for Durveqtix to treat severe and moderately severe hemophilia B, a rare genetic bleeding disorder.

The approval covers adult patients without a history of factor IX inhibitors and without detectable antibodies to variant adeno-associated virus serotype Rh74, the drugmaker said.

Durveqtix enables people with hemophilia B to produce factor IX themselves through a one-time dose instead of multiple intravenous FIX infusions weekly or biweekly with the current standard of care, the company said.

Pfizer ( PFE ) shares were up about 1.6% in recent trading.

Price: 30.46, Change: +0.48, Percent Change: +1.60